• LAST PRICE
    0.8361
  • TODAY'S CHANGE (%)
    Trending Down-0.0239 (-2.7791%)
  • Bid / Lots
    0.8315/ 1
  • Ask / Lots
    0.8499/ 13
  • Open / Previous Close
    0.8408 / 0.8600
  • Day Range
    Low 0.8312
    High 0.8500
  • 52 Week Range
    Low 0.8312
    High 1.7000
  • Volume
    35,669
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Wednesday's close: 0.86
TimeVolumeQNCX
09:45 ET40000.8408
10:03 ET1000.8499
10:15 ET5000.8499
10:28 ET1000.8499
10:33 ET1000.844999
10:35 ET1000.8499
10:39 ET2000.8401
10:44 ET12760.8391
10:57 ET2710.84
11:00 ET12000.844
11:11 ET22130.845
11:18 ET2000.84
11:20 ET6000.8399
11:24 ET12820.8399
11:31 ET1000.8356
11:33 ET24000.8398
12:00 ET1500.8312
12:05 ET24000.8399
12:20 ET2000.8399
12:27 ET3000.8399
12:30 ET1000.8399
01:01 ET5000.8378
01:06 ET1000.8399
01:15 ET6110.84
01:42 ET1000.8399
02:18 ET147090.84
02:22 ET6000.83595
02:26 ET1000.8361
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesQNCX
Quince Therapeutics Inc
37.2M
-1.1x
---
United StatesBCLI
Brainstorm Cell Therapeutics Inc
37.1M
-1.6x
---
United StatesACHL
Achilles Therapeutics PLC
37.0M
-0.6x
---
United StatesRVPH
Reviva Pharmaceuticals Holdings, Inc.
37.4M
-0.9x
---
United StatesESLA
Estrella Immunopharma Inc
36.7M
-0.5x
---
United StatesINKT
Mink Therapeutics Inc
38.1M
-1.6x
---
As of 2024-05-30

Company Information

Quince Therapeutics, Inc. is a late-stage biotechnology company. The Company is engaged in unlocking the patient’s own biology to deliver life-changing therapeutics to those living with rare diseases. Its proprietary autologous intracellular drug encapsulation (AIDE) technology platform is a drug/device combination that uses an automated process designed to encapsulate a drug into the patient’s own red blood cells. The Company’s Phase III lead asset, EryDex, leverages its AIDE technology to encapsulate dexamethasone sodium phosphate (DSP) into a patient’s own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, Ataxia-Telangiectasia (A-T). Its AIDE technology is designed to allow for the chronic administration of drugs that have limitations due to toxicity, poor biodistribution, suboptimal pharmacokinetics, or immune response. The AIDE technology platform delivers a variety of therapeutics, ranging from small to large molecules, as well as biologics.

Contact Information

Headquarters
601 Gateway Boulevard, Suite 1250SOUTH SAN FRANCISCO, CA, United States 94080
Phone
415-910-5717
Fax
302-655-5049

Executives

Independent Chairman of the Board
David Lamond
President
Charles Ryan
Chief Executive Officer, Director
Dirk Thye
Chief Financial Officer, Chief Business Officer
Brendan Hannah
Lead Independent Director
Una Ryan

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$37.2M
Revenue (TTM)
$0.00
Shares Outstanding
43.2M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.17
EPS
$-0.76
Book Value
$1.98
P/E Ratio
-1.1x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.